SIC
ALNY icon

SJS Investment Consulting’s Alnylam Pharmaceuticals ALNY Stock Holding History

SJS Investment Consulting’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.02K Buy
20
+1
+5% +$302 ﹤0.01% 1311
2026
Q1 		$6.29K Sell
19
-16
-46% -$5.45K ﹤0.01% 983
2025
Q4 		$13.9K Buy
35
+33
+1,650% +$14.6K ﹤0.01% 708
2025
Q3 		$912 Sell
2
-2
-50% -$814 ﹤0.01% 1045
2025
Q2 		$1.3K Sell
4
-3
-43% -$830 ﹤0.01% 725
2025
Q1 		$1.89K Buy
7
+3
+75% +$771 ﹤0.01% 750
2024
Q4 		$942 Sell
4
-1
-20% -$263 ﹤0.01% 1017
2024
Q3 		$1.38K Buy
5
+1
+25% +$260 ﹤0.01% 953
2024
Q2 		$972 Sell
4
-1
-20% -$158 ﹤0.01% 1036
2024
Q1 		$748 Buy
5
+2
+67% +$334 ﹤0.01% 1146
2023
Q4 		$575 Sell
3
-4
-57% -$681 ﹤0.01% 1200
2023
Q3 		$1.24K Buy
7
+2
+40% +$382 ﹤0.01% 844
2023
Q2 		$950 Buy
5
+2
+67% +$397 ﹤0.01% 919
2023
Q1 		$601 Hold
3
– – ﹤0.01% 1089
2022
Q4 		$713 Buy
3
+2
+200% +$427 ﹤0.01% 1092
2022
Q3 		$0 Buy
+1
New +$191 ﹤0.01% 1014

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SJS Investment Consulting's ALNY Position: Q2 2026 in Review

SJS Investment Consulting increased its Alnylam Pharmaceuticals (ALNY) stake by 5.3% in Q2 2026, buying an estimated $302 and bringing the position to 20 shares worth $6.02K. The position accounts for ﹤0.01% of the portfolio, ranked #1311.

SJS Investment Consulting first reported a position in ALNY in Q3 2022 and has held it in 16 quarters since. The position peaked at $13.9K in Q4 2025. 792 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • SJS Investment Consulting held 20 shares of Alnylam Pharmaceuticals worth $6.02K as of Q2 2026.
  • SJS Investment Consulting bought 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
  • Alnylam Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1311 holding.
  • SJS Investment Consulting first reported a position in Alnylam Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • SJS Investment Consulting's Alnylam Pharmaceuticals position peaked at $13.9K in Q4 2025.
  • 792 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.